American Century Companies Inc. bought a new stake in shares of The Medicines Company (NASDAQ:MDCO) during the 2nd quarter, HoldingsChannel reports. The institutional investor bought 102,157 shares of the company’s stock, valued at approximately $3,749,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Rhumbline Advisers grew its stake in The Medicines by 1.4% in the first quarter. Rhumbline Advisers now owns 158,499 shares of the company’s stock valued at $5,221,000 after purchasing an additional 2,139 shares in the last quarter. DekaBank Deutsche Girozentrale grew its stake in The Medicines by 26.7% in the first quarter. DekaBank Deutsche Girozentrale now owns 39,900 shares of the company’s stock valued at $1,332,000 after purchasing an additional 8,400 shares in the last quarter. Virginia Retirement Systems ET AL grew its stake in The Medicines by 33.8% in the first quarter. Virginia Retirement Systems ET AL now owns 53,500 shares of the company’s stock valued at $1,762,000 after purchasing an additional 13,500 shares in the last quarter. Prudential Financial Inc. grew its stake in The Medicines by 2.5% in the first quarter. Prudential Financial Inc. now owns 109,022 shares of the company’s stock valued at $3,591,000 after purchasing an additional 2,650 shares in the last quarter. Finally, Swiss National Bank grew its stake in The Medicines by 2.3% in the first quarter. Swiss National Bank now owns 126,550 shares of the company’s stock valued at $4,169,000 after purchasing an additional 2,900 shares in the last quarter.

MDCO has been the subject of a number of analyst reports. BidaskClub upgraded The Medicines from a “hold” rating to a “buy” rating in a research note on Thursday, August 16th. Citigroup raised their price target on The Medicines from $40.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, August 20th. Oppenheimer set a $50.00 price target on The Medicines and gave the company a “buy” rating in a research note on Thursday, August 16th. Zacks Investment Research upgraded The Medicines from a “hold” rating to a “buy” rating and set a $44.00 target price for the company in a research note on Tuesday, August 7th. Finally, B. Riley started coverage on The Medicines in a research note on Thursday, June 7th. They set a “buy” rating and a $55.00 target price for the company. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $52.63.

Shares of NASDAQ MDCO opened at $36.22 on Friday. The company has a quick ratio of 2.55, a current ratio of 2.60 and a debt-to-equity ratio of 31.23. The Medicines Company has a 12 month low of $24.45 and a 12 month high of $41.57. The company has a market cap of $2.79 billion, a PE ratio of -4.31 and a beta of 0.77.

The Medicines (NASDAQ:MDCO) last issued its earnings results on Wednesday, August 1st. The company reported ($0.70) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.00) by $0.30. The Medicines had a negative return on equity of 394.33% and a negative net margin of 668.93%. The company had revenue of $1.67 million during the quarter, compared to the consensus estimate of $7.20 million. During the same period in the previous year, the company posted ($0.72) EPS. The firm’s revenue for the quarter was down 84.6% compared to the same quarter last year. research analysts expect that The Medicines Company will post -2.51 EPS for the current year.

In other news, CEO Clive Meanwell sold 50,000 shares of The Medicines stock in a transaction that occurred on Monday, July 2nd. The stock was sold at an average price of $36.07, for a total transaction of $1,803,500.00. Following the completion of the transaction, the chief executive officer now directly owns 402,034 shares in the company, valued at approximately $14,501,366.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 150,000 shares of company stock valued at $5,731,000 over the last quarter. 10.29% of the stock is currently owned by corporate insiders.

The Medicines Company Profile

The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States.

Recommended Story: Short Selling – Explanation For Shorting Stocks

Want to see what other hedge funds are holding MDCO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Medicines Company (NASDAQ:MDCO).

Institutional Ownership by Quarter for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.